Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe)

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

July 31, 2009

Study Completion Date

May 31, 2012

Conditions
Metastatic Breast Cancer
Interventions
BIOLOGICAL

AdHer-2/neu transduced dendritic cells

Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)

All Listed Sponsors
collaborator

Ontario Cancer Research Network

NETWORK

collaborator

Canadian Breast Cancer Research Alliance

OTHER

lead

Ontario Clinical Oncology Group (OCOG)

OTHER

NCT00162929 - Her-2/Neu in Patients With Metastatic Breast Cancer (AdHERe) | Biotech Hunter | Biotech Hunter